Gout Through the Ages: Past, Present, and Future

Abstract

Gout is a disease unique to humans, resulting from the evolutionary loss of functional uricase, the enzyme that converts uric acid to the more soluble allantoin. This loss causes elevation of serum uric acid (SUA). With sustained hyperuricemia, deposition of monosodium urate (MSU) crystals in and around joints and extra-articular tissues occurs. Clinically, gout manifests as recurrent episodes of acute inflammatory arthritis and, when untreated or undertreated, may progress to more frequent flares, tophus formation, and structural joint damage. Persistent hyperuricemia is also linked to nephrolithiasis, chronic kidney disease progression, and increased cardiometabolic burden. This review summarizes gout across the past, the present, and the future. Historical perspectives span early descriptions dating to the Egyptian period and extend through the period just prior to the discovery of light microscopy that led to enabling identification of MSU crystals. The modern era is reviewed through the development of classification criteria; mechanisms of MSU crystal-induced inflammation; genetic determinants of urate homeostasis; and the roles of renal and intestinal urate transport in hyperuricemia. Metabolomic signatures and gut microbiota are discussed alongside current approaches to urate- lowering therapy (ULT) and flare prevention. Future directions include precision, individualized medicine integrating clinical features with molecular and imaging data to improve risk stratification and guide therapy.  They also include targeted anti-inflammatory strategies, newer ULT and uricosuric agents, and the application of metabolomics and microbiome science. Finally, the long-term possibility of uricase gene restoration as a transformative approach to reconstitute urate metabolism and potentially modify disease course is discussed.